Anti-emetics in paediatric patients receiving chemotherapy
Mené auprès de patients atteints de cancer âgés de 6 mois à 17 ans, cet essai randomisé de phase 3 analyse l'efficacité de l'aprépitant administré par voie orale pour prévenir les nausées et vomissements induits par la chimiothérapie
In The Lancet Oncology, Kang and colleagues1 describe safe and effective dosing of the neurokinin type-1 receptor antagonist aprepitant when added to a standard anti-emetic regimen for children from age 6 months to 17 years. These findings provide much-needed data for a complication that affects daily paediatric oncology practice, and show the direction for quality clinical trials in the prevention of emesis in children receiving chemotherapy. The results are impressive: prevention of emesis was doubled at nearly all endpoints with the addition of oral aprepitant, providing a 20–30% absolute improvement in control of delayed emesis and in overall 5-day complete responses.
The Lancet Oncology , commentaire, 2014